Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CASIG: a consumer-centered assessment for planning individualized treatment and evaluating program outcomes.

C J Wallace1, T Lecomte, J Wilde

  • 1UCLA Intervention Research Center for Schizophrenia, Department of Psychiatry, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024, USA. cwall886@concentric.net

Schizophrenia Research
|May 30, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardization of <sup>243</sup>Am.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort.

ESMO open·2024
Same author

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.

ESMO open·2023
Same author

"Accept voices©" group intervention for the management of auditory verbal hallucinations-results at 6 and 12 months.

Psychiatry research·2022

This study introduces a new outcome measure for serious and persistent mental illness, designed for clinical integration. It demonstrates reliable and valid psychometric properties for client and informant reports, aiding treatment planning and evaluation.

Area of Science:

  • Psychiatry and Mental Health
  • Health Services Research
  • Psychometrics

Background:

  • Existing outcome measures for serious and persistent mental illness (SPMI) often lack integration into clinical workflows.
  • There is a need for instruments that collect individualized data, guide treatment planning, and provide aggregate program data.
  • Dual-version (client self-report and informant report) measures can offer comprehensive treatment outcome assessment.

Purpose of the Study:

  • To report the psychometric characteristics of a novel outcome measure for individuals with SPMI.
  • To evaluate the measure's utility for clinical practice, program evaluation, and research.
  • To assess the reliability and validity of both client self-report and informant versions.

Main Methods:

Related Experiment Videos

  • Developed two parallel versions: client self-report and informant report.
  • Administered the self-report measure to 244 community and 93 inpatient individuals.
  • Collected informant reports for 103 community and 161 inpatient individuals.
  • Assessed reliability (internal consistency, test-retest, interrater) and validity (convergent, discriminant) using established scales (BASIS-32, SF-36, CCAR).

    • Main Results:

    • Both self-report and informant versions demonstrated acceptable internal consistency, test-retest, and interrater reliability.
    • Correlations with established measures (BASIS-32, SF-36, CCAR) provided evidence for convergent and discriminant validity.
    • Contrasts between community and inpatient samples supported the measure's discriminant validity.

    Conclusions:

    • The developed outcome measure possesses acceptable psychometric properties for assessing treatment outcomes in SPMI.
    • Its design facilitates integration into clinical processes for individualized treatment planning and evaluation.
    • The measure offers value for clinical practice, program management, and research due to its comprehensiveness, ease of administration, and continuity.